{
    "eid": "2-s2.0-84938399710",
    "title": "Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy",
    "cover-date": "2015-07-15",
    "subject-areas": [
        {
            "$": "Cancer Research",
            "@code": "1306"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [],
    "authors": [
        "Tony Mok"
    ],
    "citedby-count": 438,
    "ref-count": 27,
    "ref-list": [
        "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma",
        "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR",
        "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial",
        "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study",
        "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial",
        "First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung",
        "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations",
        "Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC",
        "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial",
        "National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China",
        "Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? - A literature-based meta-analysis",
        "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage",
        "Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer",
        "Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)",
        "Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer",
        "Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status",
        "Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping",
        "Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002",
        "Noninvasive detection of response and resistance in egfrmutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA",
        "Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer",
        "Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial",
        "Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays",
        "Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status",
        "Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma",
        "A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer",
        "Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A Multivariate analysis from the randomized GCLLSG CLL8 trial",
        "J Thorac Oncol"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Beijing",
            "affilname": "Beijing Chest Hospital, Capital Medical University",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shanghai",
            "affilname": "Shanghai Pulmonary Hospital",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shanghai",
            "affilname": "Shanghai Chest Hospital",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "Philippine General Hospital",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Guangzhou",
            "affilname": "Guangdong Provincial People\u2019s Hospital of Southern Medical University",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Surabaya",
            "affilname": "Universitas Airlangga",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Goyang",
            "affilname": "National Cancer Center, Gyeonggi",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "San Francisco",
            "affilname": "Genentech, Inc",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Pleasanton",
            "affilname": "Roche Molecular Systems",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "F. Hoffmann-La Roche AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Chinese University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": null,
            "affilname": "Roche Products Ltd",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Quezon City",
            "affilname": "Lung Centre of the Philippines",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Boulevard",
            "affilname": "Rizal Medical Center",
            "affiliation-country": "Philippines"
        }
    ],
    "funding": []
}